Sentence examples for estimates of relapse from inspiring English sources

Estimates of relapse rates for each severity category over time were generated from the overall survival function and the proportion of relapses of that category to that time point.

5 6 Although most of these studies provided crude estimates of relapse,  a few also estimated using person-years (PY) of observation, giving relapse rates of 0.65 3.0 per 100 PY for PB leprosy.

Bacteriological parameters are useful in smear positive multibacillary (MB) leprosy, whereas in PB leprosy the criteria for relapse depend primarily on clinical features since even histological examination cannot clearly distinguish between reaction and relapse. 2 There are wide variations in estimates of relapse rates in different regions.

The Kaplan Meier estimates of relapse-free survival at 3 years were 93% in patients with VEGF levels <1040 pg/mL and 40% in patients with VEGF levels ≥1040 pg/mL at 6 months post treatment (HR=12.81; 95% CI 2.691 to 90.96; p=0.0001, figure 2).

A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy.

Sixteen (69.6%) patients are alive, including nine patients in refractory and progressive disease and seven patients in complete or PR before transplant.. One-year estimate of relapse was 21.7% for all patients.

A power analysis was conducted using estimates of annual relapse rates obtained from the literature.

Areas where the current literature was limited were the robust investigation of uncertainty, including time horizons that included outcomes beyond the end of pregnancy, including major morbidities for the mother and her infant, and incorporating better estimates of postpartum relapse.

A post hoc Kaplan Meier survival analysis was performed to estimate probability of relapse during 18 months of open-label treatment with lurasidone.

The results of a Kaplan Meier analysis found a low estimated probability of relapse during 18 months of continuation treatment with lurasidone, both as monotherapy (18.3%) and adjunctive with lithium or valproate (29.1%).

In a post hoc Kaplan Meier analysis, the estimated probability of relapse on lurasidone monotherapy and adjunctive therapy at 6 months was 14.6 and 15.4%, respectively; at 12 months, it was 18.3 and 23.4%, respectively; and at 18 months, it was 18.3 and 29.1%, respectively.